Pharma Update
Roche poised for a leading role in Ophthalmology
990
980
댐
OL
Roche
Opportunities
⚫ aVEGF therapies:
transformed patient
outcomes over 15-years
• Unmet need:
superior efficacy and
durability
Changing landscape:
aging population,
diabetic epidemic, fast
progressing science
•
•
•
Products and data
Vabysmo:
nAMD, DME approved
RVO filing completed
Susvimo:
nAMD approval paused
DME, DR filing planned
Investment in RWE and
VOYAGER study
⚫ Phil data expected '24:
ASO fB GA, anti-IL-6 DME
•
Capabilities
Leading in-house
imaging data mastery:
Al applications, fluid &
genetic biomarkers
Cell based and
optogenetic gene
therapy
•
Leadership ambition
Near-term:
Vabysmo as IVT SOC
relaunch of Susvimo
• Accelerate pipeline
internally & externally:
lead RWE supporting
value of innovation
Leverage partnering
•
Expand into adjacent
ophthalmology areas
expanding with
satralizumab into TED
•
Ph III anti-IL-6 in UME
aVEGF-anti-vascular endothelial growth factor A; nAMD-neovascular age-related macular degeneration; DME=Diabetic macular edema; UME-Uveitic macular edema; DR-diabetic retinopathy; RVO-Retinal vein occlusion;
GA=geographic atrophy; IL-6-inter-leukin-6; ASO=Antisense oligonucleotide; fB-Factor B; Al-Artificial Intelligence; IVT-Intravitreal; SoC-Standard of care; RWE-Real World Evidence; TED-Thyroid eye disease
120View entire presentation